IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2024 | $12.00 | Buy | H.C. Wainwright |
| 9/24/2024 | $12.00 | Buy | Maxim Group |
H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach. Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections. Additionally, it can also be caused by multiple rounds of chemotherapy, and dep
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting. This patent application addresses a critical challenge in cell therapy: the risk of instant IBMIR, which can lead to complications such as complement activation
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced third quarter 2024 financial results and provided a corporate update. Third Quarter 2024 and Recent Highlights Joined the Russell 2000® Index effective at the
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with vascularization and the generation of a diverse array of mature T cells in animal models. The artificial thymus org
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEquity Conference Date: October 30, 2024Location: New York, NYFormat: Company PresentationTime: 10:30 a.m. ET BIO-Europe 2024Date: November 5, 2024Location: Stockholm, Swede
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the European Patent Office (Patent Number 19795975.2) covering methods and compositions for the treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual. This method uses modified fibroblasts to deliver tumor-inhibiting agents directly to cancer cell
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O'Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET. For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected]. About FibroBiologics Based in Houston, FibroBiologics is a
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference taking place October 7-9 in Phoenix, Arizona. "We always look forward to attending this very informative and collaborative meeting. For this year's meeting we will present an update of our pre-clinical IND-enabling studies in chronic wound healin
HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has engaged with Southern Star Research to provide clinical research organization (CRO) services for FibroBiologics in Australia. Initial CRO services will include preparatory work for a Phase 1/2 clinical trial utilizing product candidate, CYWC628, to treat diabetic foot ulcers. Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said,
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells. The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cell
10-Q - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
EFFECT - FibroBiologics, Inc. (0001958777) (Filer)
POS AM - FibroBiologics, Inc. (0001958777) (Filer)
10-Q - FibroBiologics, Inc. (0001958777) (Filer)
ARS - FibroBiologics, Inc. (0001958777) (Filer)
DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team. "The addition of Ruben as our General Counsel rep
- SEC Filing
Company Holds 150+ Patents For Fibroblast-Based Therapeutics And Cures For Chronic Diseases
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Vail Resorts, Inc. (NYSE:MTN) fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its third quarter. The company posted quarterly earnings of $9.54 per share, missing market estimates of $10.03 per share. The company’s sales came in at $1.28 billion versus expectations of $1.30 billion, according to data from Benzinga Pro. Vail Resorts shares declined 6.8% to $180.77 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Biomea Fusion, Inc. (NASDAQ:BMEA) shares tu
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million. Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million. American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million. Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million. Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The marke
- SEC Filing